A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease

Trial Profile

A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs ABT 957 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AbbVie
  • Most Recent Events

    • 30 Jun 2016 Status changed from recruiting to discontinued due to insufficient target engagement of ABT-957 (preclinical data).
    • 19 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2016.
    • 12 Jan 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017, according to ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top